Trending stocks today
Ocugen (OCGN-Q)
NASDAQ:OCGN
0.73
0.01
(1.55%) 1d
Financials
Technical Analysis
This summary was created by AI, based on 2 opinions in the last 12 months.
Ocugen, a small-cap biotech company, is focused on developing innovative gene therapies, cell therapies, and vaccines. Currently, the company is generating very limited revenue and is experiencing significant cash burn, totaling $62M over the last 12 months. With a balance sheet showing only $18M in cash, it is likely that Ocugen will need to issue additional shares soon to sustain its research efforts. While the stock has benefited from early clinical successes in its Phase I/II trials, the size of these trials remains small and the outcomes can lead to highly volatile stock performance, often having binary results based on the success or failure of its research. Insiders hold about 2% of the stock and have been recent sellers, raising further concerns about the stock's stability and future performance. Investors should approach this stock with caution, as the risks are considered extremely high.
$1.920
Unknown
OCGN operates as a small-cap biotech company that focuses on developing novel genes, cell therapies, and vaccines. OCGN generates very limited revenue. OCGN is still burning cash ($62M in the last 12 months), and issuing shares to support its research. The balance sheet has $18M in cash, and, given the burn rate, OCGN should be expected to issue more shares soon. The stock has done very well on early clinical success. But trials are still Phase I/II, and trials are actually quite small. Its focus is on gene therapy with retinal (eye) applications. In such scenarios, stocks are often binary: soaring on good results, crashing on bad results. Insiders own about 2% and have been recent sellers. We do not know this one well enough to recommend but risks need to be considered extremely high.
Unlock Premium - Try 5i Free
- «
- ‹
- 1
- ›
- »
Ocugen(OCGN-Q) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 2
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 2
Ocugen(OCGN-Q) Frequently Asked Questions
What is Ocugen stock symbol?
Ocugen is a American stock, trading under the symbol OCGN-Q on the NASDAQ (OCGN). It is usually referred to as NASDAQ:OCGN or OCGN-Q
Is Ocugen a buy or a sell?
In the last year, 2 stock analysts published opinions about OCGN-Q. 2 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Ocugen.
Is Ocugen a good investment or a top pick?
Ocugen was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Ocugen.
Why is Ocugen stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Ocugen worth watching?
In the last year, there was no coverage of Ocugen published on Stockchase.
What is Ocugen stock price?
On 2025-02-18, Ocugen (OCGN-Q) stock closed at a price of $0.729.
OCGN operates as a small-cap biotech company that focuses on developing novel genes, cell therapies, and vaccines. OCGN generates very limited revenue. OCGN is still burning cash ($62M in the last 12 months), and issuing shares to support its research. The balance sheet has $18M in cash, and, given the burn rate, OCGN should be expected to issue more shares soon. The stock has done very well on early clinical success. But trials are still Phase I/II, and trials are actually quite small. Its focus is on gene therapy with retinal (eye) applications. In such scenarios, stocks are often binary: soaring on good results, crashing on bad results. Insiders own about 2% and have been recent sellers. We do not know this one well enough to recommend but risks need to be considered extremely high.
Unlock Premium - Try 5i Free